Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects With Relapsed or Refractory Haematological Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects With Relapsed or Refractory Haematological Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD-4573 (Primary)
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Hairy cell leukaemia; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Richter's syndrome; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca

    • Most Recent Events

    • 13 Dec 2022 Results (At data cutoff Sept 30, 2021) assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of AZD4573 in patients (pts) with relapsed or refractory hematological malignancies, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 21 Oct 2021 Status changed from recruiting to completed.
    • 26 Aug 2021 Planned End Date changed from 1 Feb 2022 to 2 Mar 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top